返回Google圖書搜尋

Absenteeism Associated with Gynecologic Cancer in the United States

出版	University of Washington Libraries, 2022
URL	http://books.google.com.hk/books?id=IB4d0AEACAAJ&hl=&source=gbs_api

註釋Diagnosis of gynecologic cancer (GC) has been associated with employment disruption (decrease in work hours or cessation of work altogether) and identified as a substantial contributor to financial hardship. To our knowledge, no studies to date have quantified absenteeism (time spent off work due to illness) or the attributable indirect cost following a diagnosis of GC. To quantify the incremental impact of non-metastatic and metastatic gynecologic cancer (nmGC and mGC) on absenteeism, in the year following diagnosis, among commercially insured women in the US. Methods: Retrospective cohort study using MarketScan health insurance claims data. Incident GC patients were identified between May 1st, 2016 to December 31st, 2019 and followed for up to one year after diagnosis. Non-cancer controls were matched 3:1 to GC cases. Mean annual workdays lost was calculated as the sum of days missed due to nonrecreational absenteeism, short-term, and long-term disability during the follow-up period. The indirect cost attributable to workdays lost was calculated assuming an 8-hour workday and using the US average hourly wage (May 2022). Kaplan-Meier sample average technique was employed to calculate workdays lost while accounting for participants who were censored during follow-up, and bootstrapping was performed to generate 95% confidence intervals (CI). In the year following GC diagnosis, on average, women with nmGC lost 6.1 (95% CI: 5.4 - 6.7) incremental workdays, corresponding to an indirect cost of $1,555 (95% CI: $1,390 - $1,720), and women with mGC experienced more absenteeism, having 17.6 (95% CI: 14.6 - 20.8) incremental workdays lost with an indirect cost of $4,497 (95% CI: $3,727 - $5,314). We found that women with non-metastatic or metastatic gynecologic cancer missed significantly more workdays when compared with matched non-cancer controls. This analysis primarily assessed full-time employees with employer-sponsored private health insurance and disability benefits, therefore the results may not be generalizable to the broader US population. The results of this analysis may be used to inform societal perspective economic models.